Phase 2 N=145 Evaluating Safety and Effectiveness of Octenidine Dihydrochloride
Preoperative Skin Preparation
Primary: Percentage of Abdominal Site Responder Rates at 10 Minutes — 79.2; 85.4; 52.6 percentage of abdomen sites
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=313 A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
Psoriasis
Primary: Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 — 25; 44; 41; 45 Participants — p=<0.0001
Phase 2 N=87 H-1337 Ophthalmic Solution Phase 1/2
Glaucoma, Open-Angle
Primary: Intraocular Pressure (IOP) — -4.45; -5.16; -4.93; -0.39 mm Hg
Phase 2 N=41 Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
Scar Prevention
Primary: Expert Panel Scar Assessment Score at Week 12: Part B — 37.8; 42.1 millimeter — p=0.168
Phase 2 N=18 MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
Anxiety
Primary: Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint — -8.8; -23.5 score on a scale
Phase 2 N=13 A Pilot Study of Terazosin for Parkinson's Disease
Parkinson Disease
Primary: Incidence of Intervention-related Adverse Events Between Treatment Arms — 11; 4 Event
Phase 2 N=213 A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain
Osteoarthritis of the Knee
Primary: The Mean Change From Baseline Pain Score to Pain Score at the End of the Double-blind Randomized Treatment Period. — -0.06; -0.01 Change in Pain Score
Phase 2 N=180 2013/2017 H7N9 Prime-Boost Interval
Avian Influenza · Influenza Immunisation
Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutinin Inhibition (HAI) Antibodies Against the Influenza A/H7N9 Study Vaccine Viruses on Day 43 in Participants Who Received…
Phase 2 N=25 Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery
Scar Prevention
Primary: Expert Panel Scar Assessment Score at Week 12 — 36.6; 51.4 millimeter — p=<0.001
Phase 2 N=181 Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
COVID-19
Primary: All Cause-death or Invasive Mechanical Ventilation — 9; 12 Participants — p=0.5207
Phase 2 N=170 Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Lymphadenopathy
Primary: Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study — 25 mg/m^2
Phase 2 N=15 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
Hyperprolactinemia · Prolactinoma
Primary: Percentage of Subjects That Achieved PRL Normalization as Defined by a Serum Prolactin Level Less Than 25ng/mL at Any Time Point During the Study Treatment Period. — 6…
Phase 2 N=12 Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects
Degeneration Articular Cartilage Knee
Primary: IKDC Score — 32.0; 25.5 score on a scale
Phase 2 N=20 RA-2 13-cis Retinoic Acid (Isotretinoin)
Male Infertility · Klinefelter's Syndrome · Y-chromosome Microdeletions
Primary: Millions of Sperm Per Ejaculate — 2.5; 3.8 Millions of sperm per ejaculate
Phase 2 N=97 GB001 in Adult Participants With Chronic Rhinosinusitis
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Primary: Change From Baseline to Week 16 in Sino-Nasal Outcome Test (SNOT) 22 Total Score — -18.1; -18.3 score on a scale — p=0.9499